CARsgen’s Satri-cel Becomes the First Approved CAR-T Therapy for Solid Tumors 

China Marks a Historic Milestone in Cancer Immunotherapy

China’s National Medical Products Administration has approved CARsgen Therapeutics’ satricabtagene autoleucel (satri-cel; CT041), making it the world’s first CAR-T cell therapy authorized for treating a solid tumor. The therapy is indicated for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma patients whose disease has progressed after at least two prior treatment lines. This approval represents a major breakthrough, demonstrating that CAR-T technology can successfully extend beyond blood cancers into challenging solid tumors.

How Satri-cel Targets Advanced Gastric Cancer

Satri-cel is an autologous CAR-T therapy engineered to recognize Claudin18.2, a protein highly expressed in gastric and pancreatic cancers while remaining limited in normal tissues. The treatment incorporates a humanized CAR construct with CD28 and CD3ζ signaling domains for targeted tumor destruction. Patients also receive a specialized preconditioning regimen including low-dose nab-paclitaxel, cyclophosphamide, and fludarabine, designed to improve CAR-T cell infiltration and activity within the immunosuppressive tumor microenvironment.

According to Towards Healthcare, the CAR T-cell therapy for solid tumors market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.83 billion in 2026 to approximately USD 17.98 billion by 2035, representing a compound annual growth rate (CAGR) of 28.9% from 2026 to 2035.driven by advancing immunotherapy innovations, expanding clinical research, increasing oncology investments, and rising demand globally. Growing regulatory support, strategic collaborations, enhanced manufacturing capabilities, expanding treatment accessibility, favorable reimbursement initiatives, and continuous product innovation further accelerate adoption.

Clinical Evidence Supports Regulatory Approval

The approval was supported by a randomized confirmatory study published in The Lancet in 2025. In heavily pretreated patients with advanced gastric or gastroesophageal junction adenocarcinoma, satri-cel demonstrated clinically meaningful efficacy alongside a manageable safety profile compared with existing treatment options. The findings provide compelling proof that engineered cellular therapies can overcome long-standing biological barriers associated with solid tumors, opening new possibilities for patients with limited therapeutic alternatives.

Expanding Development Beyond China

CARsgen is advancing satri-cel through multiple clinical studies involving gastric, gastroesophageal junction, and pancreatic cancers in China and internationally. The therapy has also received RMAT and Orphan Drug designation from the U.S. FDA, alongside PRIME and Orphan Medicinal Product status in Europe. With global development accelerating and competing programs emerging, Satri-Cel establishes an important proof-of-concept that could reshape future treatment strategies across multiple solid tumor indications.

A recent report by Towards Healthcare highlights that the CAR T-cell therapy for solid tumors market is witnessing growth due to increasing clinical trial activity, technological advancements, rising cancer prevalence, and investments. Improved target antigen identification, combination therapy development, stronger biotechnology partnerships, expanding research funding, and favorable clinical outcomes support growth.